Merck & Co Inc has entered into a multi-year research collaboration with Cerevance Inc, a six-year-old neuroscience company, to identify novel targets for Alzheimer’s disease. Cerevance was launched by Takeda Pharmaceutical Company Ltd and Lightstone Ventures in 2016 to develop novel therapeutics for neurological and psychiatric disorders.
